Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib

Annals of Oncology

Volumn 17, Issue 7, 2006, Pages 1120-1127

  Cappuzzo, Federico ^a,b   Toschi, L ^a,b   Tallini, G ^b   Ceresoli, G L ^c   Domenichini, I ^d   Bartolini, S ^b   Finocchiaro, G ^b   Magrini, E ^b   Metro, G ^b   Cancellieri, A ^b   Trisolini, R ^b   Crino, L ^b   Bunn Jr , P A ^a   Santoro, A ^c   Franklin, W A ^a   Varella Garcia, M ^a   Hirsch, F R ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b BELLARIA HOSPITAL   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d CINECA   (Italy)

Author keywords

EGFR; Gefitinib; IGFR 1; Non small cell lung cancer; PTEN; Tyrosine kinase inhibitor

Indexed keywords

BIOLOGICAL MARKER; GEFITINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 33745615848     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl077     Document Type: Article

References (60)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
2. Shepherd FA, Pereira J, Ciuleanu TE et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123-132.
3. Sandler AB, Gray R, Brahmer J et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc Am Soc Clin Oncol 2005; 23 (Abstr).
4. Salomon D, Gullick W. The erbB family of receptors and their ligands: multiple targets for therapy. Signal 2001; 2: 4-11.
5. Arteaga C. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Sem Oncol 2002; 29: 3-9.
6. Hirsch FR, Scagliotti GV, Langer CJ et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: Perspectives for targeted therapies. Lung Cancer 2003; 41 (Suppl 1): S29-S42.
7. Ciardello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-2970.
8. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
9. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149-2158.
10. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 2004; S20-S23.
11. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
12. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
13. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
14. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer. Molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144.
15. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: E17.
16. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: E73.
17. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
18. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′ -kinase/Akt pathway signaling. Clin Cancer Res 2003; 9: 4340-4346.
19. Bianco R, Shin I, Ritter CA et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22: 2812-2822.
20. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62: 200-207.
21. Dufourny B, Alblas J, van Teeffelen HA et al. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 1997; 272: 31163-31171.
22. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21: 215-244.
23. Baserga R, Hongo A, Rubini M et al. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997; 1332: F105-F126.
24. Blakesley VA, Stannard BS, Kalebic T et al. Role of the IGF-I receptor in mutagenesis and tumor promotion. J Endocrinol 1997; 152: 339-344.
25. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995; 16: 3-34.
26. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-163.
27. Cappuzzo F, Magrini E, Ceresoli GL et al. AKT phosphorylation and gefitinib efficacy in patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2004; 6: 1133-1141.
28. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-1167.
29. Rocha RL, Hilsenbeck SG, Jackson et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 1997; 3: 103-109.
30. Turner BC, Haffty BG, Narayanan L et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57: 3079-3083.
31. Li J, Yen C, Liaw D. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
32. Steck PA, Pershouse MA, Jasser SA et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-362.
33. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57: 2124-2129.
34. Eng. C. Genetics of Cowden syndrome: Through the looking glass of oncology. Int J Oncol 1998; 12: 701-710.
35. Yi HK, Kim SY, Hwang PH et al. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. Biochem Biophys Res Commun 2005; 330: 760-767.
36. Bepler G, Sharma S, Cantor A et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 1878-1885.
37. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006; 51: 181-191.
38. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316-2326.
39. Soria JC, Lee HY, Lee JI et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002; 8: 1178-1184.
40. Jain A, Tindell CA, Laux I. Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci USA 2005; 102: 11858-11863.
41. Therasse P. New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 2000; 92: 205-216.
42. Travis WD, Colby TV, Corrin B et al. Histological Typing of Lung and Pleural Tumors, third edition. Berlin: Springer 1999.
43. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-3807.
44. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1985; 53: 457-481.
45. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
46. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-5909.
47. Jones HE, Goddard L, Gee JM et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 2004; 11: 793-814.
48. Lu Y, Zi X, Zhao Y et al. 2001 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natnl Cancer Inst 2001; 19 1852-1857.
49. Ferraro B, Bepler G, Sharma S, Cantor A, Haura EB. EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol 2005; 23: 1921-1926.
50. Tsurutani J, Fukuoka J, Tsurutani H et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 2006; 24: 306-314.
51. Tsao AS, McDonnell T, Lam S et al. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: Implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 2003; 12: 660-664.
52. Olaussen KA, Soria JC, Morat L et al. Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC. Anticancer Res 2003; 23: 4885-4890.
53. Brodt P, Samani A, Navab R. Inhibition of the type I insulin-like growth factor receptor expression and signaling: Novel strategies for antimetastatic therapy. Biochem Pharmacol 2000; 60: 1101-1107.
54. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54: 133-137.
55. Resnik JL, Reichart DB, Huey K et al. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998; 58: 1159-1164.
56. Ahlen J, Wejde J, Brosjo O et al. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res 2005; 11: 206-216.
57. All-Ericsson C, Girnita L, Seregard S et al. Insulin-like growth factor-1 receptor in uveal melanoma: A predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 2002; 43: 1-8.
58. Turner BC, Haffty BG, Narayanan L et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57: 3079-3083.
59. Hakam A, Yeatman TJ, Lu L et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30: 1128-1133.
60. Bonifacino JS, Weissman AM. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu Rev Cell Dev Biol 1998; 14: 19-57.